Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026

Moderna, Inc.

2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.
mNEXSPIKE captured ~24% of U.S. retail COVID shots and ~33% of 65+ segment.
Secured $1.5B five-year term loan; GAAP opex to fall below $5.5B in 2025 from $7.2B in 2024.
Cash cost target: ~$4.2B in 2026 and $3.5-3.9B in 2027; cash breakeven targeted in 2028.
Pipeline: Phase 3 flu efficacy positive; intismeran Phase 2b data and nine oncology readouts expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.